$
23.400
-0.23(-0.973%)1D
  • Overview
  • Forecast
  • Valuation
  • Earnings
Line
Line
|
Candle
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
23.435
Open
23.330
VWAP
23.37
Vol
713.89K
Mkt Cap
1.50B
Low
23.190
Amount
16.68M
EV/EBITDA(TTM)
10.30
Total Shares
636.29M
EV
11.97B
EV/OCF(TTM)
10.03
P/S(TTM)
4.66
Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.
Show More

Market Estimates

Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q2
FY2025Q3
FY2025Q4
911.25M
+15.32%
0.389
+22.57%
970.48M
+21.71%
0.503
+76.38%
1.04B
+16.07%
0.254
-69.59%
Estimates Revision
The market is revising Downward the revenue expectations for Genmab A/S (GMAB) for FY2025, with the revenue forecasts being adjusted by -2.28% over the past three months. During the same period, the stock price has changed by 13.43%.
Revenue Estimates for FY2025
Revise Downward
down Image
-2.28%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+2.05%
In Past 3 Month
Stock Price
Go Up
up Image
+13.43%
In Past 3 Month
6 Analyst Rating
up Image
31.07% Upside
Wall Street analysts forecast GMAB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMAB is 30.67 USD with a low forecast of 25.00 USD and a high forecast of 35.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Buy
2 Hold
0 Sell
Moderate Buy
up Image
31.07% Upside
Current: 23.400
sliders
Low
25.00
Averages
30.67
High
35.00
Truist
Buy
maintain
$45 -> $46
2025-07-08
Reason
Truist raised the firm's price target on Genmab to $46 from $45 and keeps a Buy rating on the shares. The firm notes that signals are pointing to a more attractive revenue outlook for Genmab in 2025, driven largely by Darzalex and, to a lesser extent, Epkinly and Kesimpta, the analyst tells investors in a research note. The stock's current valuation does little justice to Genmab's established revenue streams, let alone the pipeline, Truist added.
JPMorgan
Neutral
downgrade
2025-06-06
Reason
JPMorgan lowered the firm's price target on Genmab to DKK 1,500 from DKK 1,700 and keeps a Neutral rating on the shares.
RBC Capital
Outperform
to
NULL
downgrade
2025-05-29
Reason
RBC Capital lowered the firm's price target on Genmab to DKK 2,000 from DKK 2,300 and keeps an Outperform rating on the shares. The firm is updating its model after Q1 results, with minimal underlying changes but now incorporating an updated USD-DKK exchange rate which significantly lowers royalty income on U.S. sales in DKK terms, the analyst tells investors in a research note.
Lake Street
initiated
$4
2025-05-20
Reason
Lake Street initiated coverage of Bolt Biotherapeutics (BOLT) with a Buy rating and $4 price target. Bolt has developed next-generation Immune-Stimulating Antibody Conjugates, or ISACs, with optimized conjugation chemistry that have enhanced activity against even lower levels of tumor antigen, the analyst tells investors. Bolt's lead next-generation ISAC, BDC-4182, has a Phase I clinic trial that is expected to start enrolling patients this quarter and Bolt has deals with Genmab (GMAB) and Toray that fund additional ISACs through early clinical development, the analyst noted.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$37 -> $35
2025-05-14
Reason
Nordea
Hold
to
Buy
upgrade
DKK 2,009
2025-05-09
Reason

Valuation Metrics

The current forward P/E ratio for Genmab A/S (GMAB.O) is 14.83, compared to its 5-year average forward P/E of 45.05. For a more detailed relative valuation and DCF analysis to assess Genmab A/S 's fair value, click here.

Forward PE

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
45.05
Current PE
14.83
Overvalued PE
75.53
Undervalued PE
14.57

Forward EV/EBITDA

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average EV/EBITDA
32.70
Current EV/EBITDA
8.12
Overvalued EV/EBITDA
60.42
Undervalued EV/EBITDA
4.98

Forward PS

StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
11.70
Current PS
3.78
Overvalued PS
18.12
Undervalued PS
5.28

Financials

Annual
Quarterly
FY2025Q1
YoY :
+18.57%
715.00M
Total Revenue
FY2025Q1
YoY :
+62.07%
188.00M
Operating Profit
FY2025Q1
YoY :
+1.56%
195.00M
Net Income after Tax
FY2025Q1
YoY :
+3.74%
3.05
EPS - Diluted
FY2025Q1
YoY :
+19.53%
257.00M
Free Cash Flow
FY2025Q1
YoY :
-1.46%
94.13
Gross Profit Margin - %
FY2025Q1
YoY :
+15.28%
34.79
FCF Margin - %
FY2025Q1
YoY :
-14.35%
27.27
Net Margin - %
FY2025Q1
YoY :
+25.59%
22.48
ROIC

Trading Trends

Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
21.2K
Volume
1
3-6
Months
0.0
Volume
0
6-9
Months
12.5K
Volume
1
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
1
2.0M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
8.0K
USD
1
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
2
16.0K
USD
Months
0-12
0
0.0
USD
Months

GMAB News & Events

Events Timeline

2025-07-16 (ET)
2025-07-16
06:31:45
Genmab reports Q2 worldwide net sales of Darzalex $3.54B
select
2025-07-01 (ET)
2025-07-01
08:19:52
Genmab CLO Birgitte Stephensen to retire, Greg Mueller to succeed
select
2025-06-15 (ET)
2025-06-15
20:11:41
Genmab announces new results fom Phase 1b/2 EPCORE NHL-2 trial
select
Sign Up For More Events

News

9.5
07-16Newsfilter
Genmab Announces Net Sales of DARZALEX® (daratumumab) for Second Quarter of 2025
9.5
07-16SeekingAlpha
Genmab reports Q2 Darzalex net sales of $3.54 billion
6.0
07-03Yahoo Finance
M.Stanley takes neutral stance on Genmab ahead of portfolio, execution updates
Sign Up For More News

FAQ

arrow icon

What is Genmab A/S (GMAB) stock price today?

The current price of GMAB is 23.4 USD — it has decreased -0.97 % in the last trading day.

arrow icon

What is Genmab A/S (GMAB)'s business?

arrow icon

What is the price predicton of GMAB Stock?

arrow icon

What is Genmab A/S (GMAB)'s revenue for the last quarter?

arrow icon

What is Genmab A/S (GMAB)'s earnings per share (EPS) for the last quarter?

arrow icon

What changes have occurred in the market's expectations for Genmab A/S (GMAB)'s fundamentals?

arrow icon

How many employees does Genmab A/S (GMAB). have?

arrow icon

What is Genmab A/S (GMAB) market cap?